Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, to Phase III trials for early-stage Parkinson's disease. This decision follows positive data from Phase IIb PADOVA and ongoing open-label extension studies. Prasinezumab targets alpha-synuclein, a key driver of Parkinson's disease progression. While the primary endpoint in PADOVA didn't reach statistical significance, positive trends in reducing motor progression were observed and sustained in long-term follow-up. The drug showed potential efficacy, particularly in patients treated with levodopa. The studies also revealed biomarker evidence of prasinezumab's impact on disease biology. More than 750 patients participated in the open-label extensions, demonstrating a favorable safety profile over extended treatment periods. Prasinezumab aims to slow Parkinson's progression by reducing alpha-synuclein buildup in the brain. The ongoing research addresses the significant unmet need for disease-modifying treatments for Parkinson's disease. Roche's commitment to neurology research includes a broad portfolio of investigational therapies for various neurological disorders.